Clinical trial · Observational
Factors Influencing Tamoxifen Adherence in Women With Breast Cancer Receiving Tamoxifen in Botswana.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of funds
Summary
Brief summary (as posted)
Botswana is an ideal location to investigate tamoxifen adherence for numerous reasons. First, in contrast to many other countries in SSA, tamoxifen is affordable and widely available to women with ER+ breast cancer in Botswana. There is also a sufficiently high prevalence of WLW HIV and breast cancer in Botswana to provide adequate power for the proposed study. Lastly, there is a well-developed medical and scientific infrastructure, both from the clinical and laboratory perspective, to allow for successful completion of this proposed study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Female | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Primary outcome
- timeFrame
- 12 months
- description
- Reduced tamoxifen adherence, measured as reduced intake of pills number will be seen in women with reduced quality of EORTC QLQ( Cancer core quality of life questionnare acronym Q-C30 life scores, increased medication side effects, and/or increased barriers to medical care. Women living with (WLW) HIV taking tamoxifen will be less adherent to tamoxifen therapy due to the higher likelihood of medication side effects
Secondary outcomes (1)
- measure
- Secondary outcome
- timeFrame
- 12 months
- description
- Women identified as poor metabolizers will have higher tamoxifen and metabolite plasma concentrations (measured as mg/ml).
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria. * All women over the age of 18, taking (or have taken) tamoxifen for treatment of ER+ breast cancer and being HIV positive * All women over the age of 18, taking (or have taken) tamoxifen for treatment of ER+ breast cancer and being HIV negative Exclusion Criteria: * Males * Women with ER negative breast cancer * Women under 18 years of age at time of study administration.
References
Publications (0)
Data not yet available